<DOC>
	<DOCNO>NCT02149225</DOCNO>
	<brief_summary>The primary objective study assess safety tolerability , feasibility biological activity ( immunogenicity ) actively personalize vaccination ( APVAC ) concept newly diagnose glioblastoma ( GB ) patient .</brief_summary>
	<brief_title>GAPVAC Phase I Trial Newly Diagnosed Glioblastoma Patients</brief_title>
	<detailed_description>This multicenter , open-label , single arm , first-in-man phase I trial investigate safety , feasibility immunogenicity novel APVAC approach patient newly diagnose GB . Primary Endpoints : - Safety : Determine safety tolerability profile patient-tailored APVAC vaccine administer immunomodulators concurrent maintenance temozolomide ( TMZ ) cycle . - Feasibility : Determine duration success rate APVAC1 APVAC2 process vaccination APVAC drug product . - Biological activity : Descriptive analysis induce T-cell response vaccination APVAC1 APVAC2 drug product plus immunomodulators . Secondary Study Objectives : - Identification biomarkers putatively predictive immunological response and/or associate clinical success failure . Analyzed biomarkers may include non-cellular parameter measure tumor , plasma serum , cellular parameter measure peripheral blood mononuclear cell ( PBMCs ) , leukapheresis sample isolate tumor-infiltrating lymphocyte ( TILs ) . - Description potential clinical activity APVAC drug product . Descriptive analysis clinical outcome patient report include OS PFS . Correlation analysis parameter immune response data may provide first hint clinical activity vaccine . After standard chemoradiotherapy TMZ complete soon start first maintenance TMZ cycle vaccination phase begin . It start first APVAC1 vaccination , follow additional APVAC2 vaccination later time point end Last Endpoint Evaluation Visit ( LEEV ) patient . Single vaccination APVAC vaccine consist intradermal ( i.d . ) injection personalize APVAC drug product skin thigh , shoulder abdomen follow subcutaneous ( s.c. ) injection 1.5 mg poly-ICLC ( Hiltonol® ) close proximity vaccination site . The second immunomodulator GM-CSF ( 75 μg ) apply i.d . APVAC vaccination site 10-30 min injection APVACs .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Poly ICLC</mesh_term>
	<mesh_term>Poly I-C</mesh_term>
	<mesh_term>Immunologic Factors</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Carboxymethylcellulose Sodium</mesh_term>
	<mesh_term>Adjuvants , Immunologic</mesh_term>
	<criteria>1 . Histologically confirm , newly diagnose GB ( astrocytoma WHO grade IV ) 2 . HLA phenotype define warehouse composition ( HLAA*02:01 HLAA*24:02 positive patient ; determine PCRbased 4digit type method ) 3 . Gross total resection ( define less 1 cm2 residual tumor mass large perpendicular ax postoperative scan take within 48 h postsurgery ; standard MRI conformable present national international guideline sufficient ) 4 . At least 0.5 g tumor tissue freshly cryopreserved surgery 5 . Age ≥18 year 6 . KPS ≥70 % 7 . Life expectancy &gt; 6 month 8 . Patient candidate willing receive standard CRT TMZ follow maintenance TMZ cycle 9 . Patient steroid stable decrease steroid level exceed 2 mg/day dexamethasone ( equivalent dos steroid ) last 3 day prior enrollment 10 . Absolute lymphocyte count ( ALC ) &gt; 1.0 x109/L ( rescreening lymphocyte count allow ) 11 . Ability subject understand willingness sign write informed consent study participation . Written consent legally authorize representative sufficient . 12 . Availability APVAC analysis manufacturing slot confirm sponsor 13 . Female patient postmenopausal ( menstrual period minimum 1 year ) , surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) , practice one follow medically acceptable method birth control ( hormonal method , intrauterine device doublebarrier method ) practice total abstinence 14 . Male patient willing use contraception ( condom spermicidal jelly cream ) upon study entry course study , undergone vasectomy practice total abstinence 1 . Abnormal ( ≥ Grade 2 CTCAE v4.0 ) laboratory value hematology , liver renal function ( serum creatinine ) . In detail follow value apply exclusion criterion : 1 . Hemoglobin &lt; 10 g/dL ( 6.2 mmol/L ) 2 . White blood cell count ( WBC ) decrease ( &lt; 3.0 x109/L ) increase ( &gt; 10.0 x109/L ) 3 . Absolute neutrophil count ( ANC ) decrease &lt; 1.5 x109/L 4 . Platelet count decrease &lt; 75 x109/L 5 . Bilirubin &gt; 1.5 x ULN ( upper limit normal accord perform lab 's reference range ) 6 . ALAT &gt; 3 x ULN 7 . ASAT &gt; 3 x ULN 8 . GGT6 &gt; 2.5 x ULN 9 . Serum creatinine increase &gt; 1.5 x ULN 2 . HIV infection active Hepatitis B C infection , active infection require oral intravenous antibiotic cause severe disease pose severe danger lab personnel work patient ' blood tissue ( e.g . rabies ) . 3 . Prior therapy glioma ( except surgery steroid ) include limited carmustine wafer immunotherapy 4 . Any condition contraindicate leukapheresis peripheral vein 5 . Concurrent participation another interventional clinical trial study drug treatment regimen . 6 . Clinically relevant autoimmune disease ( exception thyroid disease ) 7 . Immunosuppression , related prior treatment malignancy , prior drug reaction 8 . Any condition judgment investigator interfere probability individual patient may receive benefit APVAC vaccination ( e.g . high risk early disease progression / recurrence ; immunocompromised status ; anticipate compliance problem ) 9 . Serious illness condition , accord investigator , pose undue risk patient participate trial , include , limited , follow : Clinically significant cardiovascular disease New York Heart Association class IIIIV congestive heart failure Symptomatic peripheral vascular disease Severe pulmonary dysfunction Severe diabetes Severe mental retardation 10 . History malignancy ( except adequately treat basal squamous cell carcinoma carcinoma situ ) within last 5 year unless patient diseasefree 5 year 11 . Pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Actively personalize peptide vaccination</keyword>
	<keyword>Newly diagnose Glioblastoma</keyword>
	<keyword>Concurrent first line temozolomide maintenance therapy</keyword>
</DOC>